Finally, with the aim to enhance tumor autoantibody potential to develop specific antigenic/antibody repertoires as cancer vaccines based on the observation that mutated tumor suppressors such as p53 served as primers for T cell–mediated and antibody driven responses (203), several therapeutic pan-cancer vaccines based on TAAs have been evaluated in different phases of clinical trials addressing different cancer malignancies, as NY-ESO-1, Survivin, or MAGEA1 in different cancer types (204, 205). This evidence concerns the gene TP53 and cancer.